bioAffinity Technologies
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 75
- Market Cap
- $21.7M
- Introduction
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on M...
New insider Edwards James Michael claimed ownership of 13,956 shares (SEC Form 3)
RedChip Companies to air interviews with Biotricity, Inc. (NASDAQ:BTCY) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on RedChip Small Stocks, Big Moneyâ„¢ show on Bloomberg TV, July 13, 7 p.m. ET.
A Buy Rating Justified by Strong Performance and Promising Medical
Anthony Vendetti from Maxim Group reiterated a Buy rating on Daxor (DXR) with a $22.00 price target, citing strong financial performance, increased adoption of the BVA-100 system, secured government contracts, and the upcoming next-generation BVA device.
© Copyright 2024. All Rights Reserved by MedPath